Assessing Chronic Obstructive Pulmonary Disease (COPD) Mortality and Morbidity: A Review
Article Sidebar
Published
Mar 13, 2024
Downloads
Download data is not yet available.
Submit your own article
Register as an author to reserve your spot in the next issue of the Medical Research Archives.
Author RegistrationJoin the Society
The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.
Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.
MembershipMain Article Content
Abstract
From PubMed, referencing articles over the previous 4 years, 146 articles addressing morbidity and mortality of chronic obstructive pulmonary disease (COPD) were reviewed. The major topics covered in this article include the epidemiology of COPD, spirometry with ATS/ERS and GOLD staging, scoring Indices (BODE, ADO, FODEP), trajectories in the development of COPD, pathophysiology of COPD, classification of COPD phenotypes, pharmacotherapy of COPD, causes of Acute Exacerbation of COPD (AECOPD), CT Lung imaging in COPD, and COPD comorbidities. All studies are referenced allowing for greater exploration into given areas of interest (76 ref.).
Keywords:
ATS/ERS and COPD spirometry, BODE index, ADO index, FEDOP index, AECOPD, COPD comorbidities, Area Under the Curve of the Receiver Operating Characteristic (AUROC)
Article Details
How to Cite
RICHIE, Rodney C.
Assessing Chronic Obstructive Pulmonary Disease (COPD) Mortality and Morbidity: A Review.
Medical Research Archives, [S.l.], v. 12, n. 2, mar. 2024.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/5197>. Date accessed: 27 apr. 2024.
doi: https://doi.org/10.18103/mra.v12i2.5197.
Section
Review Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2163-96. doi: 10.1016/S0140-6736(12)61729-2. PMID: 23245607
3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi: 10.1016/S0 140-6736(20)30925-9. Erratum in: Lancet. 2020;396(10262):1562. PMID: 33069326
4. https://data.cdc.gov/NCHS/NCHS-Top-Five-Leading-Causes-of-Death-United-State/mc4y-cbbv/data_preview
5. Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, Diaz AA. Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality. Ann Am Thorac Soc. 2015; 12(12): 1788-95. doi: 10: 15513/AnnalsATS. 201506-388OC. PMID: 26524488
6. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lang P. Prognosis of asymptomatic and symptomatic undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med. 2017; 5(5): 426-434. doi: 10.1016/S2213-2600(17)30119-4. PMID: 28389225
7. Sood A, Assad NA, Barnes PJ, Churg A, Gordon SB, et al. ERS/ATS workshop report on respiratory health effects of household air pollution. Eur Respir J. 2018: 51(1):1700698 doi: 10.1183/139993003.00698. PMID: 29301918
8. Guo C, Yu T, Chang LY, Bo Y, Yu Z, Wong MCS, Tam T, Lao XQ. Mortality risk attributable to classification of chronic obstructive pulmonary disease and reduced lung function: A 21-year longitudinal cohort study. Respir Med. 2021;184:106471. doi: 10.1016/j.rmed.2021.106471 PMID: 34022503
9. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. Eur Respir J. 2018; 51(3): 1702681. doi: 10.1183/13993003 .02681-2017. PMID: 2944925
10. Bhatta L, Leivseth L, Mai XM, Henriksen AH, Carslake D, Chen Y, Langhammer A, Brumptom BM. GOLLD Classifications, COPD Hospitalization, and All-Cause Mortality in Chronic Obstructive Pulmonary Disease: The HUNT Study. Int J Chron Obstruct Pulmon Dis. 2020;15:225-233. doi: 10.2147/COPD.S2 28958. PMID: 32099347
11. Cheng W, Zhou A, Zeng Y, Lin L, Song Q, Liu C, Zhou A, Peng Y, Yang M, Yang L, Chen Y, Cai S, Chen P. Prediction of Hospitalization and Mortality in Patients with Chronic Obstructive Pulmonary Disease with the New Global Initiative for Chronic Obstructive Lung Disease 2023 Group Classification: A Prospective Cohort and a Retrospective Analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:2341-2352. doi: 10.2147/COPD.S42 9104. PMID: 37908629
12. Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, et al. Discriminative Accuracy of FEV1:FVC thresholds for COPD-Related Hospitalization and Mortality. JAMA. 2019; 321(24): 2438-2447. doi: 10.1001/jama.2019. 7233. PMID: 31237643
13. Odeyemi YE, Lewis O, Ngwa J, Dodd K, Gillum RF, Mehari A. Does Low FEV1 in Addition to Fixed Ratio and/or Lower Limit of Normal of FEV1/FVC Improve Prediction of Mortality in COPD? The NHANES-III)-linked-mortality Cohort. J Natl Med Assoc. 2019;111(1):94-100. doi: 10.1016/j.jnma.2018 .06.006. PMID: 30064691
14. Oh DK, Baek S, Lee SW, Lee JS, Lee SD, Oh YM. Comparison of the fixed ratio and the Z-score of FEV1/FVC in the elderly population: a long-term mortality analysis from the Third National Health and Nutritional Examination Survey. Int J Chron Obstruct Pulmon Dis. 2018;13;903-915. doi: 10.2147/COPD.S1484 21. PMID: 29559774
15. Buhr RG, Barjaktarevic IZ, Quibrera PM, Bateman LA, et al. SPIROMICS Investigators. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Am J Respir Crit Care Med. 2022;206(5):554-562. doi: 10.1164 /rccm.202201-0094OC. PMID: 35549640
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12. doi: 10.1056/NEJMoa021 322. PMID: 14999112.
17. De Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Prognostic evaluation of COPD patients: GOLD 2011 vs BODE and the COPD comorbidity index COTE. Thorax. 2014;69(9):799-804. doi: 10.1136/thoraxjnl-2014-205770. PMID: 24969641
18. Puhan MD, Hansel NN, Sobradillo P, Enright P, Lange P, et al, for the International COPD Cohorts Collaboration Working Group. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open. 2012;2(6):e002152. doi: 10.1136/ bmjopen-2012-002152
19. Marin JM, Alfageme I, Almagro P, et al. Multicomponent Indices to predict survival in COPD: the COCOMICS study. Eur Respir J. 2013;42(2):323-332. doi: 10.1183/0903.00121012
20. Sabino PG, Silva BM, Vrunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients Clinics (Sao Paulo) 2010;65(6):599-605. doi: 10.1590/S1807-59322010000600007
21. Ischaki E, Papatheodorou G, Gaki E, PapI, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest. 2007;132(1):164-169. doi: 10.1378/chest.06-2789
22. Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, et al. The Relationship between Body Composition and Clinical Parameters in Chronic Obstructive Pulmonary Disease. J Med Assoc Thai. 2016;99(4):386-93
23. Kabitz HJ, Walterspacher S, Walker D, Windisch W. Inspiratory muscle strength in chronic obstructive pulmonary disease depending on disease severity. Clin Sci (Lond). 2007;113(5):243-249. doi: 10.1042/CS 20060362
24. Xu L, Ye T, Li J, Hu Y, Xu W, Wang K, Ou C, Chen X. Identification of relevant variables and construction of a multidimensional index for predicting mortality in COPD patients. Int J Chron Obstruct Pulmn Dis. 2019; 14:1703-1711. doi: 10.2147/COPD.S215219. PMID: 31534324
25. Martinex CH, Kim V, Chen Y, Kazeronni EA, et al. Regan Investigators. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir Med. 2014; 108(3): 491-9. doi: 10.1016/j.rmed.2013 .11.003. PMID: 24280543.
26. Wijnant SRA, De Roos E, Kavousi M, Stricker BH, Terzikhan N, Lahousse L, Brusselle GG. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020; 55(1): 1901217. doi: 10.1183/13993003.01217-2019. PMID: 31601717.
27. Knox-Brown B, Amaral AF, Burney P. Concerns about PRISm. Lancet Respir Med. 2022;10(5):e51-52. doi: 10.1016/S2213-2600 (22)0013405. PMID: 35659007
28. Wan ES, Balte P, Schwartz JE, Bhatt SP, Cassano PA, Couper D, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes IN US Adults. JAMA. 2021;326(22):2287-98. doi: 10. 1001/jama.2021.20939
29. Divo MJ, Marin JM, Casanova C, Cabrera-Lopez C, Pinto-Plata VM, et al. BODE Collaborative Group. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease. Respir Res. 2022;23(1):267. doi: 10. 1186/s12931-022-02191-7. PMID: 36157533
30. Ferrera MC, Labaki WW, Han MK. Advances in Chronic Obstructive Pulmonary Disease. Annu Rev Med. 2021: 72:119-134. doi: 10.1146/ annurev-med-080919-112707. PMID: 33502902
31. Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMI, Celli BR, et al. At the Root Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;197(12):1540-1551. doi: 10.1164/rccm.2 01720-2028BPP. Erratum in: Am J Respir Crit Care Med. 2018;198(11):1463. PMID: 29406779
32. Labaki WW, Gu T, Murray S, Curtis J, et al. Causes and and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung Function Impairment. Am J Respir Crit Care Med 2023; 208(4):451-460. doi: 10.1164/rccm.202210-18870C. PMID: 37149910
33. Hogg JC. Why does airway inflammation persist after the smoking stops? Thorax. 2006; 61(2):96-7. doi: 10.1136/ thx.2005.049502. PMID: 16444703
34. Hurst JR, Perera WR, Wilknson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173(1):71-78. doi: 10.1164/ rccm.200505-704OC. PMID: 16179639
35. Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N. Chronic Obstructive Pulmonary Disease and Phenotypes: A state-of-the-Art. Pulmonology. 2020; 26(2): 95-100. doi: 10.1016/j.pulmoe.20 19.10.006. PMID: 31740261
36. Han MK, Kazerooni EA, Lynch DA, et al. Chronic Obstructive Pulmonary Disease Exacerbations in the COPDGene Study: Associated Radiologic Phenotypes. Radiology. 2011;261: doi: 10/1148/radiol.11 110173
37. Vos T, Flaxman AD, Naghovi M, Lozano R, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. Dec 2012-Jan 2013; 380; 2163-2196. doi: 10.1016/S0140-6736(12)61729-2
38. Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta-Analysis. PLoS One. 2015;10(9):e0 135065. doi: 10.1371/journal.pone.0136065. PMID: 26336076
39. Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res. 2006;29(1):52. doi: 10.1186/1465-9921-7-52. PMID: 16571126
40. Celli B, Vestbo J, Jenkins CR, Jones PW et al. Investigators of the TORCH Study. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care. 2011;183(3):317-322. doi: 10.1164/rccm.201 004-0665OC. PMID: 20813884
41. Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol. 1994; 94(6 Pt2):1183-8. doi: 10.1016/0091-6749(94)90330-1. PMID: 7798558
42. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018; 13:335-349 doi: 10.2147/COPD.S152291. PMID: 29403271
43. Tamondong-Lachica DR, Skolnik N, Hurst JR, Marchetti N, Rabe APJ, Montes de Oca M, Celli BR. GOLD 2023 Update: Implications for Clinical Practice. Int J Chron Obstruct Pulmon Dis. 2023; 18:745-754. doi: 10.2147/COPD.S 404690. PMID: 37180752
44. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R: ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6):1697-700. doi: 10.11 83/09031936.00162414. PMID: 25323230
45. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverly PM, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005; 60(12):992-997. doi: 10.1136/ thx.2005.045385. PMID: 16227327
46. Calverley PN, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. TORCH investigators. Salmeterol and fluticasone propionate and survival to chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-789 doi: 10.1056/NEJMoa063070 PMID: 17314337
47. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, et al. Bollod eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019; 7(9):745-756. doi: 10.1016/S2213-2600(19)30 190-0. PMID: 31281061
48. Bhatt SP, Rabe K, Hanania N, Vogelmeier C, Cole J, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023; 389:205-214. doi: 10.1056/NEJMoa2303951. PMID: 37272521
49. Prins HJ, Duijkers R, Lutter R, Daniels JM, van der Valk P, Schoorl M, Kerstjens HA, van der Werf TS, Boersma WG. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respir Med. 2017; 131:118-124. doi: 10.1016/j.rmed.2017.07.06 4. PMID: 28947018
50. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012; 67(11):970-976 doi: 10.1136/ thoraxjnl-2012-202103. PMID: 22895999
51. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet. 2009; 374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. PMID: 19716960
52. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014; 189(12):1503-8. doi: 10.1164/rccm.201402-0207OC. PMID: 24779680
53. Wain LV, Shrine N, Artigas MS, Erzurumlouglu AM, Noyvert B, Bossini-Castillo L, et al. Genome-wide association analysis for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat Genet. 2017; 49(3):416-425. doi: 10.1038/ng. 3787. PMID: 28166213
54. Kowalczyk MS, Higgs DR, Gingeras TR. Molecular biology: RNA discrimination. Nature. 2012; 482(7385):310-1. doi: 10.1038/ 482310a. PMID: 22337043
55. Dang X, Qu X, Wang W, Lial C, Li Y, Zhang X, Xu D, Baglole CJ, Shang D, Chang Y. Bioinformatic analysis of microRNA and mRNA Regulation in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease. Respir Res. 2017; 18(1):4. doi: 10.1186/s12931-016-0486-5. PMID: 28057018
56. Kara M, Kirkil G, Kalemci S. Differential Expression of MicroRNAs in Chronic Obstructive Pulmonary Disease. Adv Clin Exp Med. 2016; 25(1):21-6. doi: 10.17219/acem/2 8343 PMID: 26935494
57. Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, et al. COSYCONET Study Group. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics Proteomics Boinformatics. 2018; 16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. PMID: 29981854
58. Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, et al. COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016; 114:27-37. doi: 10.1016/j.rmed.2016.0 3.008 PMID: 27109808
59. Mirra D, Esposito R, Spaziano G, La Torre C, Vocca C, Tallarico M, Clone E, Gallelli L, D’Agostino D. Lung microRNAs Expression in Lung Cancer and COPD: A Preliminary Study. Biomedicines. 2023;11(3):736. Doi: 10.3390/ biomedicines11030736. PMID: 36979715
60. Leitao Filho FS, Alotaibi NM, Ngan D, et al. Sputum microbiome is associated with 1-year mortality following COPD hospitalizations. Am J Respir Crit Care Med. 2019;199(10):1205-1213. doi: 10.1164/rccm.2 01806-1135OC. PMID: 30376356
61. Filho F, Ra S, Mattman A, Aaron S, Reed R, Sin D. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2017;140(4):1164-1167. doi: 10.1016/j.jaci.20 17.01.046
62. Filho F, Ra S, Mattman A, Schellenberg R, Criner G, et al. Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res. 2018;19 (1):30. doi: 10.1186/ s12931-018-0733-z. PMID: 29444682
63. McCullagh B, Comellas A, Ballas , Newell J, Zimmerman B, Azar A. Antibody deficiency in patient with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE 2017;12:e0172437. doi: 10.1371/journal.pone.0172437
64. Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron S, Cameron W. A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin for Recurrent Acute Exacerbation of chronic Obstructive pulmonary Disease. PLoS ONE 2015. doi: 10.1371/journal.pone.0142205
65. Okajima Y, Come CE, Nardelli P, Sonavane SK, et al. Luminal Plugging on Chest CT Scan: Association With Lung Function, Quality of Life, and COPD Clinical Phenotypes. Chest. 2020;158(1):121-130. doi: 10.1016/j.chest.2018.12.046. PMID: 32017932
66. Galbán CI, Han MK, Boes JL, Chughtai KA, Meyer Cr, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012; 18(11):1 711-5 doi: 10.1038/nm.2971. PMID: 23042237
67. Vasilescu DM, Martinez FJ, Marchetti N, Galbán CJ, Hatt C, et al. Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019: 200(5):575-581. doi: 10.1164/rccm.201811-2083OC. PMID: 30794432
68. Koo HJ, Lee SM, Seo JB, Lee SM, Kim N, Oh SY, Lee JS, Oh YM. Prediction of Pulmonary Function in Patients with Chronic Obstructive Pulmnary Disease: Correlation with quantitative CT Parameters. Korean J Radiol. 2019;20(4):683-692. doi: 10.3348/kjr.2 018.0391. PMID: 30887750
69. González G, Ash SY, Vegas-Sánchez-Ferrero G, Onieva J, Rahaghi FN, Ross JC, Díaz A, San José Estépar R, Washko GR. COPDGene and ECLIPSE Investigators. Disease Staging and Prognosis in Smokers Using Deep Learning in Chest Computed Tomography. Am J Respir Crit Care Med. 2018; 197(2):193-203 doi: 1164/rccm.20170 5-0850OC PMID: 28892454
70. André S, Conde B, Fragoso E, Boléo-Tomé JP, Areias V, Cardoso J; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD and Cardiovascular Disease. JvPulmonology. 2019 May-Jun; 25(3):168-176. doi: 10.1016/j. pulmoe.2018.09.006 PMID: 30527374.
71. Labaki WW, Gu T, Murray S, Curtis J, et al. Causes of and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung function Impairment. Am J Respir Crit Care Med. 2023; 208(4):451-460. doi: 10.1164/rccm.202210-18870C. PMID: 37149910
72. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4):1995-2004. doi: 10.1378/chest.128.4. 1995 PMID: 1623847
73. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(10):982-8. doi: 10.1164/ rccm.201206-1113OC. PMID: 22983959
74. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018 Jan-Dec;12:175346 5817750524. doi: 10.1177/17534658177505 24. PMID: 29355081
75. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631-9. doi: 10.1016/S2213-2600(15)00241-6. PMID: 26208998.
76. Vivodtzev I, Tamisier R, Baguet JP, Borel JC, Levy P, Pépin JL. Arterial stiffness in COPD. Chest. 2014 Apr;145(4):861-875. doi: 10.1378/chest.13-1809. PMID: 24687708.
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2163-96. doi: 10.1016/S0140-6736(12)61729-2. PMID: 23245607
3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi: 10.1016/S0 140-6736(20)30925-9. Erratum in: Lancet. 2020;396(10262):1562. PMID: 33069326
4. https://data.cdc.gov/NCHS/NCHS-Top-Five-Leading-Causes-of-Death-United-State/mc4y-cbbv/data_preview
5. Martinez CH, Mannino DM, Jaimes FA, Curtis JL, Han MK, Hansel NN, Diaz AA. Undiagnosed Obstructive Lung Disease in the United States. Associated Factors and Long-term Mortality. Ann Am Thorac Soc. 2015; 12(12): 1788-95. doi: 10: 15513/AnnalsATS. 201506-388OC. PMID: 26524488
6. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lang P. Prognosis of asymptomatic and symptomatic undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med. 2017; 5(5): 426-434. doi: 10.1016/S2213-2600(17)30119-4. PMID: 28389225
7. Sood A, Assad NA, Barnes PJ, Churg A, Gordon SB, et al. ERS/ATS workshop report on respiratory health effects of household air pollution. Eur Respir J. 2018: 51(1):1700698 doi: 10.1183/139993003.00698. PMID: 29301918
8. Guo C, Yu T, Chang LY, Bo Y, Yu Z, Wong MCS, Tam T, Lao XQ. Mortality risk attributable to classification of chronic obstructive pulmonary disease and reduced lung function: A 21-year longitudinal cohort study. Respir Med. 2021;184:106471. doi: 10.1016/j.rmed.2021.106471 PMID: 34022503
9. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. Eur Respir J. 2018; 51(3): 1702681. doi: 10.1183/13993003 .02681-2017. PMID: 2944925
10. Bhatta L, Leivseth L, Mai XM, Henriksen AH, Carslake D, Chen Y, Langhammer A, Brumptom BM. GOLLD Classifications, COPD Hospitalization, and All-Cause Mortality in Chronic Obstructive Pulmonary Disease: The HUNT Study. Int J Chron Obstruct Pulmon Dis. 2020;15:225-233. doi: 10.2147/COPD.S2 28958. PMID: 32099347
11. Cheng W, Zhou A, Zeng Y, Lin L, Song Q, Liu C, Zhou A, Peng Y, Yang M, Yang L, Chen Y, Cai S, Chen P. Prediction of Hospitalization and Mortality in Patients with Chronic Obstructive Pulmonary Disease with the New Global Initiative for Chronic Obstructive Lung Disease 2023 Group Classification: A Prospective Cohort and a Retrospective Analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:2341-2352. doi: 10.2147/COPD.S42 9104. PMID: 37908629
12. Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, et al. Discriminative Accuracy of FEV1:FVC thresholds for COPD-Related Hospitalization and Mortality. JAMA. 2019; 321(24): 2438-2447. doi: 10.1001/jama.2019. 7233. PMID: 31237643
13. Odeyemi YE, Lewis O, Ngwa J, Dodd K, Gillum RF, Mehari A. Does Low FEV1 in Addition to Fixed Ratio and/or Lower Limit of Normal of FEV1/FVC Improve Prediction of Mortality in COPD? The NHANES-III)-linked-mortality Cohort. J Natl Med Assoc. 2019;111(1):94-100. doi: 10.1016/j.jnma.2018 .06.006. PMID: 30064691
14. Oh DK, Baek S, Lee SW, Lee JS, Lee SD, Oh YM. Comparison of the fixed ratio and the Z-score of FEV1/FVC in the elderly population: a long-term mortality analysis from the Third National Health and Nutritional Examination Survey. Int J Chron Obstruct Pulmon Dis. 2018;13;903-915. doi: 10.2147/COPD.S1484 21. PMID: 29559774
15. Buhr RG, Barjaktarevic IZ, Quibrera PM, Bateman LA, et al. SPIROMICS Investigators. Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Am J Respir Crit Care Med. 2022;206(5):554-562. doi: 10.1164 /rccm.202201-0094OC. PMID: 35549640
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12. doi: 10.1056/NEJMoa021 322. PMID: 14999112.
17. De Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Prognostic evaluation of COPD patients: GOLD 2011 vs BODE and the COPD comorbidity index COTE. Thorax. 2014;69(9):799-804. doi: 10.1136/thoraxjnl-2014-205770. PMID: 24969641
18. Puhan MD, Hansel NN, Sobradillo P, Enright P, Lange P, et al, for the International COPD Cohorts Collaboration Working Group. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open. 2012;2(6):e002152. doi: 10.1136/ bmjopen-2012-002152
19. Marin JM, Alfageme I, Almagro P, et al. Multicomponent Indices to predict survival in COPD: the COCOMICS study. Eur Respir J. 2013;42(2):323-332. doi: 10.1183/0903.00121012
20. Sabino PG, Silva BM, Vrunetto AF. Nutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patients Clinics (Sao Paulo) 2010;65(6):599-605. doi: 10.1590/S1807-59322010000600007
21. Ischaki E, Papatheodorou G, Gaki E, PapI, Koulouris N, Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest. 2007;132(1):164-169. doi: 10.1378/chest.06-2789
22. Pothirat C, Chaiwong W, Phetsuk N, Liwsrisakun C, et al. The Relationship between Body Composition and Clinical Parameters in Chronic Obstructive Pulmonary Disease. J Med Assoc Thai. 2016;99(4):386-93
23. Kabitz HJ, Walterspacher S, Walker D, Windisch W. Inspiratory muscle strength in chronic obstructive pulmonary disease depending on disease severity. Clin Sci (Lond). 2007;113(5):243-249. doi: 10.1042/CS 20060362
24. Xu L, Ye T, Li J, Hu Y, Xu W, Wang K, Ou C, Chen X. Identification of relevant variables and construction of a multidimensional index for predicting mortality in COPD patients. Int J Chron Obstruct Pulmn Dis. 2019; 14:1703-1711. doi: 10.2147/COPD.S215219. PMID: 31534324
25. Martinex CH, Kim V, Chen Y, Kazeronni EA, et al. Regan Investigators. The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir Med. 2014; 108(3): 491-9. doi: 10.1016/j.rmed.2013 .11.003. PMID: 24280543.
26. Wijnant SRA, De Roos E, Kavousi M, Stricker BH, Terzikhan N, Lahousse L, Brusselle GG. Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study. Eur Respir J. 2020; 55(1): 1901217. doi: 10.1183/13993003.01217-2019. PMID: 31601717.
27. Knox-Brown B, Amaral AF, Burney P. Concerns about PRISm. Lancet Respir Med. 2022;10(5):e51-52. doi: 10.1016/S2213-2600 (22)0013405. PMID: 35659007
28. Wan ES, Balte P, Schwartz JE, Bhatt SP, Cassano PA, Couper D, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes IN US Adults. JAMA. 2021;326(22):2287-98. doi: 10. 1001/jama.2021.20939
29. Divo MJ, Marin JM, Casanova C, Cabrera-Lopez C, Pinto-Plata VM, et al. BODE Collaborative Group. Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease. Respir Res. 2022;23(1):267. doi: 10. 1186/s12931-022-02191-7. PMID: 36157533
30. Ferrera MC, Labaki WW, Han MK. Advances in Chronic Obstructive Pulmonary Disease. Annu Rev Med. 2021: 72:119-134. doi: 10.1146/ annurev-med-080919-112707. PMID: 33502902
31. Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMI, Celli BR, et al. At the Root Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;197(12):1540-1551. doi: 10.1164/rccm.2 01720-2028BPP. Erratum in: Am J Respir Crit Care Med. 2018;198(11):1463. PMID: 29406779
32. Labaki WW, Gu T, Murray S, Curtis J, et al. Causes and and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung Function Impairment. Am J Respir Crit Care Med 2023; 208(4):451-460. doi: 10.1164/rccm.202210-18870C. PMID: 37149910
33. Hogg JC. Why does airway inflammation persist after the smoking stops? Thorax. 2006; 61(2):96-7. doi: 10.1136/ thx.2005.049502. PMID: 16444703
34. Hurst JR, Perera WR, Wilknson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173(1):71-78. doi: 10.1164/ rccm.200505-704OC. PMID: 16179639
35. Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N. Chronic Obstructive Pulmonary Disease and Phenotypes: A state-of-the-Art. Pulmonology. 2020; 26(2): 95-100. doi: 10.1016/j.pulmoe.20 19.10.006. PMID: 31740261
36. Han MK, Kazerooni EA, Lynch DA, et al. Chronic Obstructive Pulmonary Disease Exacerbations in the COPDGene Study: Associated Radiologic Phenotypes. Radiology. 2011;261: doi: 10/1148/radiol.11 110173
37. Vos T, Flaxman AD, Naghovi M, Lozano R, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. Dec 2012-Jan 2013; 380; 2163-2196. doi: 10.1016/S0140-6736(12)61729-2
38. Alshabanat A, Zafari Z, Albanyan O, Dairi M, FitzGerald JM. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta-Analysis. PLoS One. 2015;10(9):e0 135065. doi: 10.1371/journal.pone.0136065. PMID: 26336076
39. Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res. 2006;29(1):52. doi: 10.1186/1465-9921-7-52. PMID: 16571126
40. Celli B, Vestbo J, Jenkins CR, Jones PW et al. Investigators of the TORCH Study. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care. 2011;183(3):317-322. doi: 10.1164/rccm.201 004-0665OC. PMID: 20813884
41. Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol. 1994; 94(6 Pt2):1183-8. doi: 10.1016/0091-6749(94)90330-1. PMID: 7798558
42. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018; 13:335-349 doi: 10.2147/COPD.S152291. PMID: 29403271
43. Tamondong-Lachica DR, Skolnik N, Hurst JR, Marchetti N, Rabe APJ, Montes de Oca M, Celli BR. GOLD 2023 Update: Implications for Clinical Practice. Int J Chron Obstruct Pulmon Dis. 2023; 18:745-754. doi: 10.2147/COPD.S 404690. PMID: 37180752
44. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R: ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014; 44(6):1697-700. doi: 10.11 83/09031936.00162414. PMID: 25323230
45. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverly PM, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005; 60(12):992-997. doi: 10.1136/ thx.2005.045385. PMID: 16227327
46. Calverley PN, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J. TORCH investigators. Salmeterol and fluticasone propionate and survival to chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8):775-789 doi: 10.1056/NEJMoa063070 PMID: 17314337
47. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, et al. Bollod eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019; 7(9):745-756. doi: 10.1016/S2213-2600(19)30 190-0. PMID: 31281061
48. Bhatt SP, Rabe K, Hanania N, Vogelmeier C, Cole J, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023; 389:205-214. doi: 10.1056/NEJMoa2303951. PMID: 37272521
49. Prins HJ, Duijkers R, Lutter R, Daniels JM, van der Valk P, Schoorl M, Kerstjens HA, van der Werf TS, Boersma WG. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respir Med. 2017; 131:118-124. doi: 10.1016/j.rmed.2017.07.06 4. PMID: 28947018
50. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012; 67(11):970-976 doi: 10.1136/ thoraxjnl-2012-202103. PMID: 22895999
51. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet. 2009; 374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. PMID: 19716960
52. Han MK, Tayob N, Murray S, Dransfield MT, Washko G, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014; 189(12):1503-8. doi: 10.1164/rccm.201402-0207OC. PMID: 24779680
53. Wain LV, Shrine N, Artigas MS, Erzurumlouglu AM, Noyvert B, Bossini-Castillo L, et al. Genome-wide association analysis for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nat Genet. 2017; 49(3):416-425. doi: 10.1038/ng. 3787. PMID: 28166213
54. Kowalczyk MS, Higgs DR, Gingeras TR. Molecular biology: RNA discrimination. Nature. 2012; 482(7385):310-1. doi: 10.1038/ 482310a. PMID: 22337043
55. Dang X, Qu X, Wang W, Lial C, Li Y, Zhang X, Xu D, Baglole CJ, Shang D, Chang Y. Bioinformatic analysis of microRNA and mRNA Regulation in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease. Respir Res. 2017; 18(1):4. doi: 10.1186/s12931-016-0486-5. PMID: 28057018
56. Kara M, Kirkil G, Kalemci S. Differential Expression of MicroRNAs in Chronic Obstructive Pulmonary Disease. Adv Clin Exp Med. 2016; 25(1):21-6. doi: 10.17219/acem/2 8343 PMID: 26935494
57. Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, et al. COSYCONET Study Group. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics Proteomics Boinformatics. 2018; 16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. PMID: 29981854
58. Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, et al. COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016; 114:27-37. doi: 10.1016/j.rmed.2016.0 3.008 PMID: 27109808
59. Mirra D, Esposito R, Spaziano G, La Torre C, Vocca C, Tallarico M, Clone E, Gallelli L, D’Agostino D. Lung microRNAs Expression in Lung Cancer and COPD: A Preliminary Study. Biomedicines. 2023;11(3):736. Doi: 10.3390/ biomedicines11030736. PMID: 36979715
60. Leitao Filho FS, Alotaibi NM, Ngan D, et al. Sputum microbiome is associated with 1-year mortality following COPD hospitalizations. Am J Respir Crit Care Med. 2019;199(10):1205-1213. doi: 10.1164/rccm.2 01806-1135OC. PMID: 30376356
61. Filho F, Ra S, Mattman A, Aaron S, Reed R, Sin D. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2017;140(4):1164-1167. doi: 10.1016/j.jaci.20 17.01.046
62. Filho F, Ra S, Mattman A, Schellenberg R, Criner G, et al. Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respir Res. 2018;19 (1):30. doi: 10.1186/ s12931-018-0733-z. PMID: 29444682
63. McCullagh B, Comellas A, Ballas , Newell J, Zimmerman B, Azar A. Antibody deficiency in patient with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE 2017;12:e0172437. doi: 10.1371/journal.pone.0172437
64. Cowan J, Gaudet L, Mulpuru S, Corrales-Medina V, Hawken S, Cameron C, Aaron S, Cameron W. A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin for Recurrent Acute Exacerbation of chronic Obstructive pulmonary Disease. PLoS ONE 2015. doi: 10.1371/journal.pone.0142205
65. Okajima Y, Come CE, Nardelli P, Sonavane SK, et al. Luminal Plugging on Chest CT Scan: Association With Lung Function, Quality of Life, and COPD Clinical Phenotypes. Chest. 2020;158(1):121-130. doi: 10.1016/j.chest.2018.12.046. PMID: 32017932
66. Galbán CI, Han MK, Boes JL, Chughtai KA, Meyer Cr, et al. Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med. 2012; 18(11):1 711-5 doi: 10.1038/nm.2971. PMID: 23042237
67. Vasilescu DM, Martinez FJ, Marchetti N, Galbán CJ, Hatt C, et al. Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019: 200(5):575-581. doi: 10.1164/rccm.201811-2083OC. PMID: 30794432
68. Koo HJ, Lee SM, Seo JB, Lee SM, Kim N, Oh SY, Lee JS, Oh YM. Prediction of Pulmonary Function in Patients with Chronic Obstructive Pulmnary Disease: Correlation with quantitative CT Parameters. Korean J Radiol. 2019;20(4):683-692. doi: 10.3348/kjr.2 018.0391. PMID: 30887750
69. González G, Ash SY, Vegas-Sánchez-Ferrero G, Onieva J, Rahaghi FN, Ross JC, Díaz A, San José Estépar R, Washko GR. COPDGene and ECLIPSE Investigators. Disease Staging and Prognosis in Smokers Using Deep Learning in Chest Computed Tomography. Am J Respir Crit Care Med. 2018; 197(2):193-203 doi: 1164/rccm.20170 5-0850OC PMID: 28892454
70. André S, Conde B, Fragoso E, Boléo-Tomé JP, Areias V, Cardoso J; GI DPOC-Grupo de Interesse na Doença Pulmonar Obstrutiva Crónica. COPD and Cardiovascular Disease. JvPulmonology. 2019 May-Jun; 25(3):168-176. doi: 10.1016/j. pulmoe.2018.09.006 PMID: 30527374.
71. Labaki WW, Gu T, Murray S, Curtis J, et al. Causes of and Clinical Features Associated with Death in Tobacco Cigarette Users by Lung function Impairment. Am J Respir Crit Care Med. 2023; 208(4):451-460. doi: 10.1164/rccm.202210-18870C. PMID: 37149910
72. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128(4):1995-2004. doi: 10.1378/chest.128.4. 1995 PMID: 1623847
73. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186(10):982-8. doi: 10.1164/ rccm.201206-1113OC. PMID: 22983959
74. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018 Jan-Dec;12:175346 5817750524. doi: 10.1177/17534658177505 24. PMID: 29355081
75. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631-9. doi: 10.1016/S2213-2600(15)00241-6. PMID: 26208998.
76. Vivodtzev I, Tamisier R, Baguet JP, Borel JC, Levy P, Pépin JL. Arterial stiffness in COPD. Chest. 2014 Apr;145(4):861-875. doi: 10.1378/chest.13-1809. PMID: 24687708.